NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
Tribe Public CEO Presentation & Q&A: Hosted Friday, August 21
Tribe Public hosted its CEO Presentation and Q&A webinar, “Food Shouldn’t Hurt: EOE, Eupraxia, and a Promising New Treatment Approach,” featuring James Helliwell, MD, Chief Executive Officer of Eupraxia Pharmaceuticals Inc. (NASDAQ:…
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
Tenon Medical, Inc. (NASDAQ: TNON) is had the sort of trading day that causes even seasoned small-cap investors to refresh their screens twice. Shares closed up $5.96, or 109.36%, to $11.41, after hitting an intraday high of $16.28..Volume exceeded 48.4 million shares—roughly…
U.S. stocks finished broadly higher on Wednesday, August 19, as a pullback in long-dated Treasury yields improved risk appetite, a pause in proposed Canadian tariffs reduced a near-term trade overhang, and a landmark oncology update sparked an extraordinary biotech rally. The S&P…
Amwell, Inc. (NYSE: AMWL, $12.40, up +152.55% YTD) is building a more investable telehealth narrative: less pandemic-era novelty, more enterprise healthcare infrastructure. Its second-quarter results suggest the company is translating a broad digital-care footprint into a steadier mix of recurring subscription revenue,…
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has delivered the kind of Phase 3 result biotechnology investors wait patiently—and, on occasion, not so patiently—for. The company reported that avexitide reduced the composite rate of severe and clinically meaningful post-bariatric hypoglycemia events by 55% versus…
Doximity, Inc. (NYSE: DOCS) is making a persuasive case that clinical AI can be both useful to physicians and financially disciplined enough to interest Wall Street. Its fiscal 2027 first-quarter report delivered accelerating revenue growth, resilient profitability and a sharp rise in…
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) offer investors two distinctly attractive versions of the same biotech proposition: value creation through disciplined execution. Jazz is deploying capital to deepen an established rare-epilepsy franchise, while Eupraxia is assembling the…